Value proposition
goes FAR BEYOND
(Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases)
Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed.
Dimicare Biotech is building a great team involving Microbiology Medical doctors, Fundamental researchers, and Financial experts, assuring solid growth not only in the scientific but also in the business field.
Currently, our projects have been awarded by the Innovation program from Labex SIGNALIFE (Young Entrepreneur Program) and we are currently searching for new funding to support the continuity of the project.
If you are interested in our research and want to contact us for collaboration or just to talk, do not hesitate to contact me through any of the options available in my profile.
Microbiology, Antimicrobial Resistance, Bacteria, Fungi, Parasites, Drug Development, and Medicinal ChemistryOriginal language
goes FAR BEYOND
(Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases)
Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed.
Dimicare Biotech is building a great team involving Microbiology Medical doctors, Fundamental researchers, and Financial experts, assuring solid growth not only in the scientific but also in the business field.
Currently, our projects have been awarded by the Innovation program from Labex SIGNALIFE (Young Entrepreneur Program) and we are currently searching for new funding to support the continuity of the project.
If you are interested in our research and want to contact us for collaboration or just to talk, do not hesitate to contact me through any of the options available in my profile.
Home
Antibiotics, Resistance, Precision treatment, emergent pathogen, infectious disease, Drug Discovery, Biotech, HealthTech, Innovation, Research, Microbiology, Pharmacology, Infection,
https://www.dimicare-biotech.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Métropole Nice Côte d'Azur Government Administration, French metropolis | Métropole Nice Côte d'Azur Government Administration, French metropolis | Other 22 Nov 2024 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Other 22 Nov 2024 | | |
 Région Sud - Provence-Alpes-Côte d'Azur National and local authorities, Government Administration | Région Sud - Provence-Alpes-Côte d'Azur National and local authorities, Government Administration | Other 17 Feb 2025 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 22 Nov 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 17 Feb 2025 | | |
 | Rise Partners | Other 22 Jan 2024 | | |
 Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 16 Feb 2024 | | |
 Caisse d’Epargne Banking | Caisse d’Epargne Banking | Other 22 Jan 2024 | | |
 Inria Research, Research Services | Inria Research, Research Services | Other 22 Jan 2024 | | |
 Orange Telecoms, Law Practice, Telecommunications | Orange Telecoms, Law Practice, Telecommunications | Other 22 Jan 2024 | | |